Pathologic Function
Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment
Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist
Amgen’s Uplizna Achieves Success in Phase 3 Trial for Immunoglobulin G4-Related Disease (IgG4-RD)
Amgen, Uplizna, IgG4-RD, Phase 3 Trial, Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Lilly’s Tirzepatide Demonstrates Efficacy in Mid-Stage MASH Study
Tirzepatide, MASH, Eli Lilly, Fibrosis, Liver Disease, Diabetes, Obesity
RYBREVANT: A Breakthrough in Lung Cancer Treatment
RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)
BridgeBio’s Infigratinib Demonstrates Sustained Efficacy in Phase 2 Trial for Achondroplasia Treatment
BridgeBio, Infigratinib, Achondroplasia, Hypochondroplasia, Phase 2 Trial, Growth Disorder Treatment
Blackstone Invests $300M in Uniquity Bio to Unleash Merck Drug’s Inflammation & Immunology Potential
Blackstone, Uniquity Bio, Merck, Inflammation & Immunology, Investment, Drug Development, Biotechnology
Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment
Chiesi, Gossamer, pulmonary hypertension, drug development, investment, collaboration, GD-001, clinical trials, cardiovascular diseases.
Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition
Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million
Enlivex Stock Plunges 50% Following Mixed Phase II Sepsis Results for Allocetra Cell Therapy
Enlivex Therapeutics, Allocetra Cell Therapy, Phase II Study, Sepsis Treatment, Stock Plummet, Mixed Results, Septic Shock, Urinary Tract Infection (UTI)
Verve Temporarily Halts Lead Base Editing Study Following Adverse Event, Prioritizes Alternative Therapy
Verve Therapeutics, Lead base editing program, Adverse event, VERVE-101, Serious adverse events (SAEs), Grade 3 ALT elevation, Thrombocytopenia, Pause enrollment in Heart-1 study, Alternative therapy focus: VERVE-102, Ionizable lipid delivery system, Phase Ib Heart-2 clinical trial, Q2 2024 initiation of Heart-2 clinical trial.